Your browser is no longer supported. Please, upgrade your browser.
Settings
GLYC [NASD]
GlycoMimetics, Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own0.10% Shs Outstand51.56M Perf Week1.84%
Market Cap91.47M Forward P/E- EPS next Y-1.38 Insider Trans264.90% Shs Float50.61M Perf Month-17.41%
Income-61.60M PEG- EPS next Q-0.34 Inst Own62.20% Short Float1.46% Perf Quarter-27.19%
Sales1.30M P/S70.36 EPS this Y16.60% Inst Trans-4.24% Short Ratio1.11 Perf Half Y-40.50%
Book/sh1.87 P/B0.89 EPS next Y-5.70% ROA-48.00% Target Price11.00 Perf Year-55.01%
Cash/sh1.85 P/C0.90 EPS next 5Y- ROE-53.30% 52W Range1.45 - 4.40 Perf YTD-55.85%
Dividend- P/FCF- EPS past 5Y-10.70% ROI-40.20% 52W High-62.27% Beta1.90
Dividend %- Quick Ratio10.80 Sales past 5Y-12.70% Gross Margin- 52W Low14.48% ATR0.11
Employees54 Current Ratio10.80 Sales Q/Q-90.00% Oper. Margin- RSI (14)38.36 Volatility7.53% 6.11%
OptionableYes Debt/Eq0.00 EPS Q/Q-16.40% Profit Margin- Rel Volume0.38 Prev Close1.66
ShortableYes LT Debt/Eq0.00 EarningsNov 02 BMO Payout- Avg Volume667.27K Price1.66
Recom2.20 SMA20-9.64% SMA50-14.08% SMA200-29.23% Volume256,143 Change0.00%
Nov-12-21Upgrade Jefferies Hold → Buy $3 → $4
Nov-14-19Initiated ROTH Capital Buy $12
Aug-05-19Downgrade SunTrust Buy → Hold $23 → $5
Aug-05-19Downgrade Piper Jaffray Overweight → Neutral $20 → $6
Aug-05-19Downgrade Jefferies Buy → Hold
Apr-12-19Initiated Piper Jaffray Overweight $20
Dec-18-18Initiated H.C. Wainwright Buy $24
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
Dec-06-21 09:15AM  
Nov-24-21 08:00PM  
Nov-23-21 04:30PM  
Nov-22-21 04:15PM  
Nov-15-21 07:00AM  
Nov-11-21 09:00AM  
Nov-09-21 09:00AM  
07:03AM  
Nov-02-21 02:00PM  
07:30AM  
Oct-26-21 09:00AM  
Sep-29-21 01:14PM  
Sep-24-21 06:57AM  
Sep-23-21 04:00PM  
Sep-10-21 08:10AM  
Sep-08-21 09:00AM  
Aug-23-21 08:38AM  
Aug-09-21 09:00AM  
Aug-07-21 12:00PM  
Aug-05-21 07:30AM  
Aug-04-21 04:15PM  
Jul-29-21 04:30PM  
Jul-22-21 09:00AM  
Jul-12-21 09:00AM  
02:50AM  
May-27-21 07:08PM  
May-26-21 09:00AM  
May-20-21 08:11AM  
May-13-21 11:15AM  
May-12-21 02:13AM  
May-05-21 06:03AM  
May-03-21 02:30PM  
07:30AM  
06:30AM  
Apr-26-21 09:00AM  
Apr-10-21 09:00AM  
09:00AM  
Mar-31-21 04:48PM  
Mar-10-21 04:30PM  
Mar-04-21 08:30AM  
Mar-02-21 05:30PM  
07:30AM  
06:30AM  
Feb-26-21 04:30PM  
Feb-24-21 12:46AM  
Feb-23-21 04:30PM  
09:00AM  
Jan-10-21 03:25AM  
Jan-07-21 07:10AM  
Dec-11-20 08:32PM  
Dec-07-20 04:30PM  
Dec-05-20 06:00PM  
Nov-26-20 12:40AM  
Nov-10-20 04:00PM  
Nov-06-20 07:31PM  
07:30AM  
06:30AM  
Nov-04-20 01:03PM  
Oct-30-20 09:00AM  
Oct-26-20 09:00AM  
Oct-12-20 07:28AM  
Oct-06-20 10:31AM  
08:24AM  
Oct-05-20 04:30PM  
Sep-08-20 04:00PM  
Sep-04-20 09:00AM  
Aug-31-20 09:00AM  
Aug-28-20 08:56AM  
Aug-06-20 05:19PM  
Jul-31-20 06:30PM  
08:00AM  
Jul-24-20 09:15AM  
Jul-22-20 10:45AM  
Jul-10-20 09:00AM  
Jun-30-20 06:30PM  
08:48AM  
Jun-12-20 12:23PM  
08:41AM  
May-29-20 09:00AM  
May-15-20 12:30PM  
May-12-20 03:48AM  
May-08-20 08:30AM  
May-05-20 07:18AM  
May-01-20 09:01PM  
07:00AM  
Apr-30-20 09:00AM  
Apr-24-20 09:00AM  
Apr-07-20 09:15AM  
Apr-06-20 04:15PM  
Mar-26-20 01:51AM  
Mar-11-20 07:36AM  
Feb-28-20 08:07AM  
Feb-25-20 09:00AM  
Feb-11-20 07:23AM  
Feb-06-20 10:40AM  
Feb-04-20 09:53AM  
Jan-30-20 09:00AM  
Jan-06-20 05:14PM  
03:02PM  
09:00AM  
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Andrews Patricia SDirectorNov 16Buy2.0540,00082,00045,250Nov 18 04:05 PM
King Rachel K.President, CEODec 28Option Exercise1.12130,821146,520440,240Dec 30 04:00 PM
King Rachel K.President, CEODec 28Sale3.9184,176329,128356,064Dec 30 04:00 PM
Hahn Brian M.SVP Finance, CFODec 16Option Exercise1.125,2605,8915,260Dec 17 04:00 PM